Stocksigma LogoStocksigma Logo

Suven Life Sciences to Present Key Alzheimer's Clinical Data at CTAD-2026

Suven Life Sciences announced on 16th Nov'26 that it will present clinical trial progress for two key CNS drug candidates at the CTAD conference in Boston

Suven Life Sciences to Present Key Alzheimer's Clinical Data at CTAD-2026

Suven Life Sciences Ltd 路 Press Release 路 16 Nov 2026, 4:28 pm

Suven Life Sciences to Present Key Alzheimer's Clinical Data at CTAD-2026 Suven Life Sciences announced on 16th Nov'26 that it will present clinical trial progress for two key CNS drug candidates at the CTAD conference in Boston. The company completed enrollment for its global Phase-3 study of Masupirdine (SUVN-502) targeting agitation in Alzheimer's dementia, with topline results scheduled for Q2'27 and no major safety concerns identified to date. Additionally, Phase-1 SAD and MAD safety, tolerability, and pharmacokinetic data for Tenaclidine (SUVN-I6107) will be presented as it prepares to advance into patient trials.

Original exchange filing (PDF)

More announcements from Suven Life Sciences Ltd

All Suven Life Sciences Ltd announcements